In order to further confirm our findings and ensure that the observed PIK3CA-mutant-specific effect was not confounded by the genomic backgrounds of the selected cell lines, we investigated whether activation of PI3K via knock-in of the c.3140A>G (p.H1047R) or c.1633G>A (p.E545K) mutation could sensitize a PIK3CA wild-type colon cancer cell line to aspirin treatment. The gene discussed is PIK3CG; the disease is colonic neoplasm.